Antiphospholipid syndrome
MONDO:8000010A disorder caused by the presence of autoantibodies directed against phospholipids, causing a hypercoaguable state, which may result in blood clots, stroke, heart attack, and in women, significant pregnancy-related complications, including miscarriage and still birth. The syndrome is often associated with other autoimmune disorders, most commonly lupus erythematosus, and infections, including syphilis and Lyme disease.
Also known as: Hughes syndrome, antiphospholipid antibody syndrome, antiphospholipid syndrome, familial lupus anticoagulant, lupus anticoagulant, familial
94 clinical trials for this condition and its sub-types, 58 tagged with Antiphospholipid syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Antiphospholipid syndrome
-
Primary antiphospholipid syndrome 4 trials
-
Familial antiphospholipid syndrome 0 trials
-
Secondary antiphospholipid syndrome 0 trials
1 sub-type
- Neonatal antiphospholipid syndrome 0 trials
-
New drug RAY121 tested for Long-Term control of autoimmune diseases
Disease control By invitation onlyThis study is a long-term extension of an earlier trial, testing the safety of a drug called RAY121 in people with six different immune system disorders, including antiphospholipid syndrome and immune thrombocytopenia. Participants have already completed four doses of RAY121 and …
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental biologic aims to stop recurrent clots in antiphospholipid syndrome
Disease control OngoingThis early-phase trial tests an investigational biologic called EA5 in adults with antiphospholipid syndrome (APS) who have had two or more blood clots despite standard blood-thinning therapy. The study enrolls about 12 participants and gives EA5 by intravenous infusion followed …
Phase 1 • Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Withdrawn study: could hydroxychloroquine help High-Risk pregnancies?
Disease control CancelledThis study was designed to see if adding hydroxychloroquine to standard treatment (aspirin and heparin) could help women with antiphospholipid syndrome have a healthy full-term pregnancy. It planned to enroll pregnant women before 14 weeks of gestation. However, the trial was wit…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Blood clot drug trial for rare autoimmune disease pulled before start
Disease control CancelledThis study aimed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in people with antiphospholipid syndrome (APS). APS is an autoimmune disease that increases clot risk. The trial was withdrawn before enrolling any participants, so no re…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a common antiplatelet drug replace warfarin after APS-Related stroke?
Prevention OngoingAntiphospholipid syndrome (APS) raises the risk of blood clots and strokes, and doctors often prescribe warfarin to prevent another stroke. Warfarin requires frequent blood tests and carries bleeding risks, especially for younger patients. This trial compares clopidogrel-based an…
Phase 4 • Sponsor: Seoul National University Hospital • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
New MRI study seeks hidden stroke causes in rare blood disorder
Knowledge-focused By invitation onlyThis study looks at why people with antiphospholipid syndrome (APS) — a condition that raises blood clot risk — may have narrowed brain arteries. Researchers will use advanced MRI scans on 60 APS patients to check for artery narrowing and plaque buildup. The goal is to better und…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Rare disease pregnancy study pulled before it began
Knowledge-focused CancelledThis study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC